A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 143,900 shares of APLS stock, worth $3.96 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
143,900
Previous 218,300 34.08%
Holding current value
$3.96 Million
Previous $8.37 Million 50.44%
% of portfolio
0.0%
Previous 0.0%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$28.84 - $41.15 $1.28 Million - $1.82 Million
44,242 Added 28.75%
198,133 $5.71 Million
Q2 2024

Aug 14, 2024

SELL
$38.07 - $59.71 $39.3 Million - $61.6 Million
-1,032,191 Reduced 87.03%
153,891 $5.9 Million
Q1 2024

May 15, 2024

BUY
$55.39 - $72.47 $49.9 Million - $65.3 Million
900,965 Added 316.0%
1,186,082 $69.7 Million
Q4 2023

Feb 14, 2024

BUY
$37.14 - $64.82 $10 Million - $17.5 Million
270,370 Added 1833.39%
285,117 $17.1 Million
Q3 2023

Nov 14, 2023

SELL
$23.65 - $89.22 $12.2 Million - $45.8 Million
-513,825 Reduced 97.21%
14,747 $560,000
Q2 2023

Aug 14, 2023

BUY
$76.68 - $93.31 $27.2 Million - $33.1 Million
354,512 Added 203.67%
528,572 $48.2 Million
Q1 2023

May 15, 2023

BUY
$46.59 - $66.96 $7.86 Million - $11.3 Million
168,791 Added 3203.47%
174,060 $11.5 Million
Q4 2022

Feb 14, 2023

SELL
$43.24 - $61.04 $1.85 Million - $2.62 Million
-42,892 Reduced 89.06%
5,269 $272,000
Q3 2022

Nov 14, 2022

SELL
$44.76 - $69.66 $6.68 Million - $10.4 Million
-149,298 Reduced 75.61%
48,161 $3.29 Million
Q2 2022

Aug 15, 2022

SELL
$35.07 - $59.21 $8.13 Million - $13.7 Million
-231,793 Reduced 54.0%
197,459 $8.93 Million
Q1 2022

May 16, 2022

SELL
$35.46 - $54.12 $18.6 Million - $28.4 Million
-524,479 Reduced 54.99%
429,252 $21.8 Million
Q4 2021

Feb 14, 2022

SELL
$30.74 - $49.16 $27.8 Million - $44.5 Million
-904,701 Reduced 48.68%
953,731 $45.1 Million
Q3 2021

Nov 15, 2021

BUY
$31.4 - $69.84 $47.3 Million - $105 Million
1,505,416 Added 426.44%
1,858,432 $61.3 Million
Q2 2021

Aug 16, 2021

BUY
$40.9 - $64.9 $12.3 Million - $19.5 Million
300,464 Added 571.75%
353,016 $22.3 Million
Q1 2021

May 17, 2021

SELL
$40.8 - $57.39 $56.5 Million - $79.5 Million
-1,384,394 Reduced 96.34%
52,552 $2.26 Million
Q4 2020

Feb 16, 2021

SELL
$30.79 - $57.2 $23.6 Million - $43.8 Million
-765,312 Reduced 34.75%
1,436,946 $82.2 Million
Q3 2020

Nov 16, 2020

BUY
$25.89 - $33.65 $21.6 Million - $28 Million
832,498 Added 60.78%
2,202,258 $66.4 Million
Q2 2020

Aug 14, 2020

BUY
$24.8 - $38.49 $15.7 Million - $24.4 Million
634,920 Added 86.4%
1,369,760 $44.7 Million
Q1 2020

May 15, 2020

BUY
$17.91 - $44.33 $3.2 Million - $7.91 Million
178,480 Added 32.08%
734,840 $19.7 Million
Q4 2019

Feb 14, 2020

SELL
$22.1 - $30.8 $1.89 Million - $2.63 Million
-85,360 Reduced 13.3%
556,360 $17 Million
Q2 2019

Aug 14, 2019

SELL
$18.0 - $25.34 $5.46 Million - $7.69 Million
-303,464 Reduced 32.11%
641,720 $16.3 Million
Q1 2019

May 15, 2019

BUY
$12.81 - $19.82 $11.5 Million - $17.7 Million
894,915 Added 1780.25%
945,184 $0
Q4 2018

Feb 14, 2019

SELL
$11.47 - $18.71 $154,191 - $251,518
-13,443 Reduced 21.1%
50,269 $663,000
Q3 2018

Nov 13, 2018

BUY
$16.57 - $21.03 $869,013 - $1.1 Million
52,445 Added 465.47%
63,712 $0
Q2 2018

Aug 10, 2018

BUY
$19.63 - $30.0 $221,171 - $338,010
11,267 New
11,267 $0

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.02B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.